Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,000 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effect of glucagon-like peptide-1 on insulin secretion.
Shima K, Hirota M, Ohboshi C. Shima K, et al. Regul Pept. 1988 Aug;22(3):245-52. doi: 10.1016/0167-0115(88)90037-7. Regul Pept. 1988. PMID: 3051138
Release of glucagon-like peptide 1 immunoreactivity from the perfused rat pancreas.
Shima K, Hirota M, Ohboshi C, Sato M, Nishino T. Shima K, et al. Acta Endocrinol (Copenh). 1987 Apr;114(4):531-6. doi: 10.1530/acta.0.1140531. Acta Endocrinol (Copenh). 1987. PMID: 3577586
A large molecular form of glucagon-like peptide-1 (GLP-1) immunoreactivity is co-released with glucagon from pancreas by arginine in normal subjects.
Hirota M, Shimizu I, Ohboshi C, Nishino T, Shima K. Hirota M, et al. Clin Chim Acta. 1987 Aug 31;167(3):293-302. doi: 10.1016/0009-8981(87)90349-4. Clin Chim Acta. 1987. PMID: 3304721
Beta-endorphin in the human gallbladder.
Shimizu I, Matsumura M, Hirota M, Fujii T, Shima K. Shimizu I, et al. Regul Pept. 1986 Dec 30;16(3-4):331-8. doi: 10.1016/0167-0115(86)90033-9. Regul Pept. 1986. PMID: 2951771
When human gallbladder mucosa was perfused with a solution of 10(-8) M or 10(-6) M cholecystokinin octapeptide (CCK-8), the release of beta-END-LI from mucosa into the perfusate increased 2-3 fold. ...
When human gallbladder mucosa was perfused with a solution of 10(-8) M or 10(-6) M cholecystokinin octapeptide (CCK-8), the re …
Glucagon-degrading activity in acid-ethanol extract of rat submandibular gland.
Tahara Y, Shima K, Hirota M, Tanaka A, Ikegami H, Yamamoto Y, Fukuda M, Kumahara Y. Tahara Y, et al. Horm Metab Res. 1986 Dec;18(12):800-3. doi: 10.1055/s-2007-1012443. Horm Metab Res. 1986. PMID: 3817745
Salivary gland glucagon is a fictitious substance due to tracer-degrading activity resistant to protease inhibitors.
Tahara Y, Shima K, Hirota M, Ikegami H, Tanaka A, Kumahara Y. Tahara Y, et al. Biochem Biophys Res Commun. 1983 May 31;113(1):340-7. doi: 10.1016/0006-291x(83)90471-0. Biochem Biophys Res Commun. 1983. PMID: 6407481
Protective effect of eicosapentaenoic acid on insulin resistance in hyperlipidemic patients and on the postoperative course of cardiac surgery patients: the possible involvement of adiponectin.
Yamamoto T, Kajikawa Y, Otani S, Yamada Y, Takemoto S, Hirota M, Ikeda M, Iwagaki H, Saito S, Fujiwara T. Yamamoto T, et al. Acta Med Okayama. 2014 Dec;68(6):349-61. doi: 10.18926/AMO/53024. Acta Med Okayama. 2014. PMID: 25519029 Clinical Trial.
Relationship between activin A level and infarct size in patients with acute myocardial infarction undergoing successful primary coronary intervention.
Miyoshi T, Hirohata S, Uesugi T, Hirota M, Ohnishi H, Nogami K, Hatanaka K, Ogawa H, Usui S, Kusachi S. Miyoshi T, et al. Clin Chim Acta. 2009 Mar;401(1-2):3-7. doi: 10.1016/j.cca.2008.10.027. Epub 2008 Nov 8. Clin Chim Acta. 2009. PMID: 19028479
1,000 results
Jump to page
Feedback